Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...

An intimate bar and coffee area in the kitchen makes for a suitable backdrop for intimate gatherings, according to its listing. Spacious upper-level bedrooms have Jack-and-Jill baths. Other highlights ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

Finder.com reports on a stock-picking contest between ChatGPT and Grok using paper trading platforms to see which portfolio yields better returns over a year.